Davita Inc. (DVA) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Davita Inc. (DVA) stock forecast summary
On Oct. 13, 2026, DVA is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Davita Inc. is a large-cap company with a market capitalization of $11.62B. It ranks number 1 by market capitalization among the 11 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for DVA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, DVA included.
Follow DVA freeDVA price chart and AI forecast
How DVA ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Davita Inc. (DVA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
Valuation & Market
| Metric | DVA | Rank |
|---|---|---|
| Market Cap | $11.62B | 1/11 |
| P/E Ratio | 13.71x | 4/5 |
| EPS | $12.15 | – |
| Revenue/Share | $219.59 | – |
| FCF/Share | $25.23 | – |
Profitability & Margins
| Metric | DVA | Rank |
|---|---|---|
| ROA | 4.8% | 5/10 |
| ROIC | 14.3% | 4/8 |
| Operating Margin | 15.2% | 1/9 |
| Net Margin | 6.0% | 3/10 |
| EBT Margin | 10.5% | 3/10 |
| Tax Rate | 20.7% | – |
Financial Health
| Metric | DVA | Rank |
|---|---|---|
| Current Ratio | 1.47x | 5/11 |
| Quick Ratio | 1.41x | 2/5 |
| Interest Coverage | 1.0x | 9/12 |
| Working Capital | $1.33B | 1/11 |
Cash Flow
| Metric | DVA | Rank |
|---|---|---|
| Operating Cash Flow | $2.19B | 1/11 |
| Free Cash Flow | $1.61B | 1/7 |
| Capital Spending | -$583M | 7/7 |
| OCF Growth YoY | 17.8% | 2/7 |
| FCF Growth YoY | 25.0% | 1/5 |
| FCF/Sales | 11.5% | 3/7 |
| CapEx/Sales | 4.2% | 3/7 |
Operational Efficiency
| Metric | DVA | Rank |
|---|---|---|
| Asset Turnover | 0.79x | 5/9 |
| Receivables Turnover | 5.7x | 5/9 |
| Fixed Assets Turnover | 5.1x | 4/8 |
| Days Sales Outstanding | 64 days | 5/9 |
Income Statement
| Metric | DVA | Rank |
|---|---|---|
| Total Revenue | $14.01B | 1/9 |
| Operating Income | $2.13B | 2/10 |
| Net Income | $847M | 1/10 |
Dividend & Shareholder Information
| Metric | DVA | Rank |
|---|---|---|
| Shares Outstanding | 64M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4.19B | 23.7% of assets |
| Cash & Short-term Investments | $669M | 3.8% of assets |
| Accounts Receivable | $2.47B | 13.9% of assets |
| Inventory | $152M | 0.9% of assets |
| Total Liabilities | $16.63B | 93.9% of assets |
| Short-term Debt | $2.14B | 12.1% of assets |
DVA quarterly financials and insider trading
Davita Inc. (DVA) industry peers
Companies classified under the same SEC industry code as Davita Inc. (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| DVA Davita Inc. | ▶ | $11.62B |
| FMS Fresenius Medical Care Ag | ▼ | $5.89B |
| SHC Sotera Health Co | ▼ | $5.18B |
| PGNY Progyny, Inc. | ▶ | $2.15B |
| AGL Agilon Health, Inc. | ▶ | $1.44B |
| VMD Viemed Healthcare, Inc. | ▲ | $366M |
| PARK Park Dental Partners, Inc. | ▲ | $96M |
| MRAI Marpai, Inc. | ▲ | $87M |
| CCEL Cryo Cell International Inc | ▲ | $36M |
| PFHO Pacific Health Care Organization Inc | ▲ | $12M |
| MGRX Mangoceuticals, Inc. | ▶ | $8M |
| BRTX Biorestorative Therapies, Inc. | ▶ | N/A |
| NIVF Newgenivf Group Ltd | ▼ | N/A |
Where DVA sits on the market map
Davita Inc. (DVA) stock news
Loading...
Davita Inc. (DVA) stock forecast FAQ
What is the Davita Inc. (DVA) stock forecast?
On Oct. 13, 2026, DVA is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Davita Inc. stock predictions?
A per-ticker accuracy statistic for DVA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Davita Inc. forecasts updated?
Davita Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Davita Inc.'s industry peers?
13 issuers in our coverage, DVA included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Fresenius Medical Care Ag (FMS), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD), Park Dental Partners, Inc. (PARK).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.